TruthArchive.ai - Related Video Feed

CMS is currently offering a 20% bonus payout to hospitals that choose to use Remdesivir for Medicare aged patients. This drug is supposedly approved by the FDA and recommended by the NIH for COVID-19 treatment. However, it is known to cause kidney, heart, and liver failure. Hospitals are also being incentivized to PCR test every patient, regardless of the reason for their visit, in order to increase their numbers. The federal government pays a monthly bribe based on the percentage of PCR tests conducted. Hospitals receive a 20% bonus for every positive COVID-19 diagnosis, as well as for using Remdesivir and ventilating patients. Additionally, they receive further incentives for every COVID-19 death, amounting to $9,000 per case per month. The reasons behind these incentives remain unclear.

Transparency and outcome-based funding are key solutions. CMS data showed a 90% ventilator mortality rate in Texas, worse than Russian roulette. Hospitals are allegedly incentivized to use specific protocols. Hospitals get paid more for testing, COVID admission, remdesivir, ventilation, and death. This allegedly incentivizes patient murder over treatment. The public should decide if they want to incentivize good hospital outcomes or the alleged murder of loved ones.

Since May 2020, Remdesivir has been linked to a 30% death rate among patients receiving the drug for 5 to 10 days in hospitals. In New York, 26.9% of Medicare-aged patients who received Remdesivir died. The Cardiovascular Toxicology Journal found in October 2020 that Remdesivir is cardiotoxic and can cause death of heart cells. Despite this, the FDA and NIH continue to approve and recommend Remdesivir as the only drug for hospitalized COVID-19 patients. The World Health Organization published in April of last year that Remdesivir leads to increased acute kidney failure compared to other drugs. Shockingly, the FDA recently authorized the use of Remdesivir for newborns and children up to 18 years old.

Hospitals are receiving financial incentives for COVID-related cases, leading to concerns about patient care and transparency. The CARES Act offers bonus payments for COVID diagnoses, while the Center for Medicare and Medicaid Services is waiving patient rights. Hospitals receive payments for offering free COVID tests, diagnosing COVID, admitting COVID patients, administering Remdesivir, using mechanical ventilators, and even listing COVID on death certificates. There are also bonus payments to coroners. This combination of incentives has raised concerns about hospitals prioritizing financial gain over patient well-being. The estimated payment per patient is around $100,000. The situation is alarming, and urgent action is needed to address these issues.

A doctor claims there were "perverse incentives" during the pandemic to administer COVID vaccines. As an outpatient physician, she states she could have made $1,500,000 if she had vaccinated the 6,000 COVID patients she treated. She suggests that both outpatient and inpatient settings had "financial incentives" to adhere to government protocols.

The CDC and NVSS changed death certificate reporting in violation of federal law. Two days later, the HHS increased reimbursement for hospitals and doctors who listed everything as COVID, making it the most lucrative diagnosis. There are reports of patients being starved and denied water, possibly to increase the use of Remdesivir. The range of fraudulent death certificates is estimated to be between 88.6% and 94.0%. Reimbursement for a diabetic patient labeled as COVID is 3 to 6 times higher. Hospitals had to go along with this to stay in business. Doctors who spoke up were threatened with license revocation and faced censorship. This is seen as collusion and murder for profit.

When someone dies with COVID-19, it's counted as a COVID-19 death, not just an infection. Doctors are being paid more for listing patients as COVID-19 cases, with $13,000 for a COVID-19 admission and $39,000 if the patient goes on a ventilator. Some believe this treatment approach is wrong and could harm many people.

Since May 2020, Remdesivir has been linked to a 30% death rate among patients receiving the drug in hospitals for 5 to 10 days. In New York, 26.9% of Medicare-aged patients who received Remdesivir died. The Cardiovascular Toxicology Journal found in October 2020 that Remdesivir causes heart cell death and is cardiotoxic. However, the FDA and NIH continue to approve and recommend Remdesivir as the only drug for hospitalized COVID-19 patients, despite the World Health Organization's report in April of last year that it causes increased acute kidney failure. Shockingly, the FDA recently authorized the use of Remdesivir for newborns and children up to 18 years old.

Unvaccinated patients entering the hospital reported being treated differently based on their vaccination status. Those who had not received the COVID-19 shot were quickly given treatments like remdesivir and placed on ventilators, leading to a high mortality rate. There are claims that hospitals had financial incentives to classify deaths as COVID-related, with some receiving substantial payments for each case. Whistleblowers from within the healthcare system indicated that staff were pressured to ensure positive COVID tests to secure funding. The financial motives behind these practices raised serious ethical concerns, with one individual stating that their loved one was valued more dead than alive due to these incentives.

Since May 2020, remdesivir may result in at least 30% death in hospitalized patients who receive it for five to ten days. CMS data for Medicare patients in New York showed 26.9% of those who received remdesivir died. In October 2020, the cardiovascular toxicology journal found remdesivir causes death of heart cells, is cardiotoxic, and can lead to cardiac arrest. Despite this, in December 2020, the NIH, with Anthony Fauci, updated guidelines listing remdesivir as the only FDA-approved drug for hospitalized Americans, even though the WHO published data in April of last year that it increases acute kidney failure compared to other drugs used to treat COVID-19. As of January 21st of this year, the FDA extended emergency use authorization, making remdesivir the only authorized medication that can be administered intravenously to newborns to 18-year-olds for COVID-19.

Actions were taken to promote the vaccine by inflating COVID numbers through protocols in 2020. Hospitals were incentivized to label patients as COVID, put them on ventilators, administer Remdesivir, and profit from deaths. The goal was to instill fear and push vaccinations. Hospital administrators, driven by financial incentives, unknowingly contributed to unnecessary deaths. This greed-driven system continues to harm people.

Patients are dying not from COVID, but from treatments like remdesivir causing organ failure. One person's mother died after being given remdesivir against their wishes, leading to organ shutdown. There was a financial incentive for hospitals to admit patients and put them on ventilators, resulting in unnecessary treatments and deaths.

The stimulus bill intended to help hospitals overrun with COVID patients created an incentive to record something as COVID. Hospitals are in a bind because if a hospital is half full, it's hard to make ends meet. Checking a box can yield $8,000, and putting a patient on a ventilator for five minutes can bring $39,000. The alternative could be firing doctors. This situation presents a tough moral quandary.

Multiple studies, including one by the WHO, show that Remdesivir actually increases the risk of death. It's concerning that the federal government incentivizes hospitals to prescribe this toxic drug by offering a 20% bonus on the entire hospital bill for Medicare patients. Remdesivir costs around $3,000 per course. On the other hand, Ivermectin, as mentioned by Dr. Kory, reduces the risk of death by about 50%. Unfortunately, clinicians still use the wrong drug, Dexamethasone, in the wrong dose and for the wrong duration of time, simply because the NIH recommends it. The NIH and other agencies have disregarded multiple FDA-approved drugs that are both cost-effective and safe.

Speaker 0: There were four drugs that were being tested for Ebola. Remdesivir killed more people than placebo, and the data safety monitoring board had actually stopped the study where literally fifty three percent of Speaker 1: the patients died in the failed Ebola trial and was repurposed. It was a failed Ebola drug because it caused more harm than good in Ebola trials. It was still unpatent. It was Tony Fauci's drug of choice. The majority of hospital deaths were actually caused by Anthony Fauci because his NIH put out protocols that if the hospital systems adhered to, they got bonuses, big bonuses, lots of money, $3,000 per for putting an IV in of remdesivir. Boom. $3,000. But guess what? On top of the entire hospital stay, a 20% bonus, that could be hundreds of thousands of dollars. Speaker 0: The data was so overwhelming that remdesivir killed patients more so than placebo. The drug had to be stopped, and this was published in the New England Journal in the 2019. Speaker 2: What happened during COVID could not have happened without propaganda and censorship. And how do we overcome that propaganda and censorship? It's primarily through people not being willing to shut up.

Hospitals are receiving bonus payments for COVID cases, leading to high mortality rates and lack of transparency for families. The CARES Act incentivizes hospitals with payments for COVID tests, diagnoses, admissions, remdesivir use, ventilator use, and even COVID-related deaths on death certificates. This system is seen as the Biden administration paying hospitals to harm patients, with estimated payments of $100,000 per patient. The situation is dire and needs to be addressed urgently.

We ended our previous episode with our COVID pyramid, build layer upon layer of lies, deceit, fraud, scandals. Now, by now you’re wondering how so many hospitals, doctors, and health care workers went along with all of the above. We have reached the capstone of our nauseating COVID pyramid. Pyramid. We shall name the capstone M and M, money and murder in hospitals. Shocking as it may sound, we’ve seen it before. Remember the unjust administering the killer drug midazolam in The UK as shown in part 19? Well, The US and many other countries had their own version called remdesivir. Here’s what happened. Hospitals were given incentives, as in money, for each and every COVID casualty. According to whistleblowers, investigative journalists, lawyers, and specialists, Hospitals in The US have been receiving $13,000 for every admitted COVID patient. There have been financial extras for every COVID test, for every positive outcome. If patients were treated with the only prescribed drug, remdesivir, the hospital received yet another bonus: 20% of the entire hospital bill of the patient. Then for every patient put on a ventilator, the hospital received $39,000. And if that patient officially died of COVID nineteen, they got yet another $13,000. That’s a lot of money. According to attorney Thomas Renz and CMS whistleblowers, the hospitals receive approximately $100,000 per COVID casualty if the above protocol was followed. Now the thing is, the American hospitals received this money in advance based on the COVID predictions, based on the flawed models of people like Brooks. If the hospitals didn’t actually meet those models, they had to pay that money back at a later stage. And we’re talking millions of dollars here. So what happened? Everybody who was admitted to a hospital, for instance because of a car accident or because of cancer or diabetes or kidney failure, everybody got a PCR test to start with. Due to the ridiculous amount of cycles, there was an abundance of false positives. False positives equals positives equals COVID patients equals money. Hence, the sunrise in COVID patients. Then remdesivir left its detrimental mark just like midazolam had done in The UK. You see, remdesivir is not a new drug. It was used in 2018 during the West African Ebola outbreak. It was known to have severe adverse effects such as kidney damage, liver damage, and even death. Yet in 2020, Anthony Fauci directed that remdesivir was to be the drug hospitals used to treat COVID nineteen, hence the incentives. So what happened next? Those poor patients only got worse, after which they were put on a ventilator. After all, that was yet another bonus of many thousands of dollars pouring straight into the pockets of the hospitals. Now the problem with ventilators is that the patient is put into an induced coma. His or her breathing is taken over by a machine that puts extra pressure on the lungs called barrow pressure. In the case of damaged lungs due to for instance pneumonia, those lungs will only get worse. The chances of that patient recovering, of being able to be taken off the ventilator and to start breathing by himself are very, very small. Combined with organ failure as a result of remdesivir, the chances of that patient ever leaving the hospital alive are next to nothing.

America is counting all deaths with COVID-19 as COVID-19 deaths, not just those caused by the virus. Doctors claim they are incentivized to label patients as COVID-19 cases for financial gain, with $13,000 paid by Medicare for each COVID-19 hospital admission and $39,000 if the patient goes on a ventilator. This has led to concerns about misdiagnosis and inappropriate treatment.

Remdesivir, one of four drugs tested for Ebola, allegedly killed more people than the placebo, leading the Data Safety Monitoring Board to halt the study. According to the transcript, 53% of patients died in the failed Ebola trial, but the drug was repurposed. It is claimed that Remdesivir was Anthony Fauci's drug of choice, and that the NIH protocols, which provided hospitals with bonuses for using remdesivir, caused the majority of hospital deaths. Reportedly, hospitals received $3,000 for each remdesivir IV and a potential 20% bonus. The data allegedly showed that remdesivir killed more patients than the placebo, resulting in the drug trial being stopped. One speaker stated that it is inexplicable that remdesivir became the standard of care, and that doctors seemingly shut off their brains and followed directions from above without questioning the use of remdesivir in every hospitalized patient.

Hospitals were incentivized to put patients on ventilators for financial gain, receiving $39,000 per patient. Many patients were put on ventilators unnecessarily, leading to high death rates. Some physicians found that patients could be treated with oxygen therapy instead of ventilators. Despite spending billions on ventilators, many remain unused in warehouses or even discarded in city dumps.

Remdesivir, also known as "run death is near," played a key role in creating the illusion of a deadly pandemic. Doctors were told COVID-19 causes pneumonia and kidney failure. The hospital protocol involved renal and internal medicine consults, screening patients for kidney issues due to remdesivir's potential kidney damage. They monitored kidney function and were supposed to stop the drug if function declined. Remdesivir-induced kidney injury led to fluid buildup, often misdiagnosed as COVID-19 pneumonia. This, followed by ventilation and more drugs, became a deadly cycle. The increase in acute kidney injury deaths coincided with the rollout of the new tech bonus and later, the vaccine rollout in 2021, with unvaccinated patients possibly targeted for these protocols.

Patients were desperate for ivermectin as their loved ones died, but the focus shifted to remdesivir, a previously failed Ebola drug. By November 2020, the World Health Organization advised against its use, citing ineffectiveness and potential kidney and liver damage. The European Society of Critical Care supported this stance. Despite the warnings, the U.S. Health and Human Services incentivized hospitals with a 20% bonus for administering remdesivir, leading to widespread use. It failed to reduce mortality and caused serious injuries, with some patients dying as a result. In May 2022, the WHO reaffirmed its initial decision, stating that remdesivir should never have been used.

I've stated since May 2020 that remdesivir will result in at least 30% death in those who receive it in the hospital. I had data pulled for Medicare patients in New York, and found that 26.9% of those who received remdesivir died. As of October 2020, the cardiovascular toxicology journal found that remdesivir causes death of heart cells and can lead to cardiac arrest. Yet, in December, the NIH decided to update all guidelines for treatment drugs allowed for COVID-19, and remdesivir was the only FDA-approved drug for hospitalized Americans, despite the WHO publishing that it causes increased acute kidney failure. As of January of this year, the FDA extended an emergency use authorization, making remdesivir the only authorized medication that can be administered to newborns to 18-year-olds.

According to the speaker, hospital protocols differed for vaccinated and unvaccinated COVID-19 patients, with more aggressive protocols used on the unvaccinated. The unvaccinated patients interviewed were often given remdesivir, a repurposed drug from a failed Ebola trial where about half the patients died. The speaker claims the efficacy data for remdesivir was "sketchy at best," but hospitals received large reimbursements for its use. The speaker alleges that patients would then be put on oxygen, then mechanical ventilation, then ICU, and finally, if they resisted, a cocktail of sedatives and sometimes four-point restraints to prevent them from leaving. The speaker states that "a lot of the patients died." The speaker claims that at each step, the hospital received more reimbursement, and there was "lockstep adherence" to the protocol.

Conflicts and controversies surrounding remdesivir are significant. In November 2020, the World Health Organization conducted a comprehensive study and advised against using remdesivir in hospitals due to its association with death and kidney and liver injuries. Despite this, the U.S. incentivizes its use by offering hospitals a 20% bonus on the total bill if remdesivir is administered. As a doctor, I find it troubling that while other medications do not provide such financial incentives, the use of remdesivir can lead to substantial additional costs for hospitals, contradicting the WHO's recommendations. This situation highlights a serious disconnect in medical decision-making.